The primary goal of a recurrent pregnancy loss clinic is to identify identifiable etiologies for repeated loss events and implement evidence-based therapeutic interventions. By combining advanced diagnostic imaging, genetic sequencing, hormonal profiling, and specialized early pregnancy monitoring, clinicians transform empirical care into targeted biological management. Care protocols align with clinical guidelines established by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM).

Evaluation at a recurrent pregnancy loss clinic involves systematic diagnostic steps: 1. Comprehensive clinical history and review of miscarried tissue pathology if available. 2. Diagnostic blood work including parental karyotyping, antiphospholipid antibody panels (lupus anticoagulant, anticardiolipin, anti-beta-2-glycoprotein I), thyroid-stimulating hormone (TSH), and anti-thyroid peroxidase antibodies. 3. Anatomical evaluation using 3D transvaginal ultrasound, saline infusion sonohysterography, or diagnostic hysteroscopy to evaluate uterine architecture. 4. Assessment of male partner factors via advanced semen analysis and DNA fragmentation testing where clinically indicated. 5. Interdisciplinary review to formulate a targeted treatment plan prior to future conception attempt.

Evidence-Based Clinical Benefits

• Systematic Etiological Identification: Identifies underlying cause in up to 50% of couples undergoing thorough evaluation (ESHRE 2023).
• Targeted Pharmacotherapy: Allows precise application of antithrombotic, endocrine, or immunomodulatory protocols rather than unproven empiric treatments.
• Surgical Correction: Improves pregnancy preservation rates following hysteroscopic resection of uterine septa or submucosal fibroids.
• Structured Early Pregnancy Care: Dedicated early ultrasound surveillance and supportive care in dedicated clinical settings improve subsequent live birth outcomes (PROMISE trial clinical data).
• Psychological and Emotional Support: Integrated clinical counseling reduces psychological distress and anxiety associated with repeated losses.

Recovery and Follow-Up Timeline

Diagnostic evaluations performed in an outpatient clinic setting involve minimal physical recovery. Patients undergoing blood draws or non-invasive pelvic ultrasounds resume daily activities immediately. Minor diagnostic procedures, such as saline infusion sonohysterography or diagnostic hysteroscopy, may cause mild uterine cramping for 24 to 48 hours. When surgical interventions are required, short-term physical recovery spans 3 to 7 days, with long-term monitoring continuing through the first trimester of subsequent pregnancies.

Indications and Conditions Evaluated

• Recurrent Early Pregnancy Loss: Consecutive or non-consecutive pregnancy loss prior to 10–12 weeks of gestation.
• Late Miscarriage: Pregnancy loss occurring between 12 and 24 weeks of gestation without prior fetal death.
• Uterine Anatomical Anomalies: Congenital or acquired cavity defects including septate uterus, uterine fibroids (submucosal), and intra-uterine adhesions (Asherman syndrome).
• Antiphospholipid Syndrome (APS): Autoimmune thrombophilic conditions predisposing patients to microvascular thrombosis and placental dysfunction.
• Endocrine Disorders: Uncontrolled thyroid dysfunction, hyperprolactinemia, and luteal phase defects.
• Parental Chromosomal Rearrangements: Balanced reciprocal or Robertsonian translocations in either biological parent.
• Unexplained Recurrent Pregnancy Loss: Repeated losses where standard diagnostic testing reveals no identifiable structural, genetic, or endocrine cause.

Patients preparing for evaluation at a recurrent pregnancy loss clinic should gather all relevant past medical records, operative notes, miscarried tissue genetic reports, and prior ultrasound scans. Blood panels for antiphospholipid syndrome require testing at least 12 weeks apart, and testing should occur at least 6 weeks following a pregnancy loss to avoid transient physiological baseline shifts. Hormonal evaluations are typically scheduled during specific phases of the menstrual cycle, such as day 2–5 for baseline follicle-stimulating hormone and luteinizing hormone assessments.

Standard diagnostic evaluation at an RPL clinic carries low clinical risk. Venipuncture for blood panels carries minor risks of localized bruising, phlebotomy site pain, or rare localized phlebitis. Transvaginal ultrasound causes minimal discomfort. Invasive diagnostic procedures such as saline infusion sonohysterography or hysteroscopy carry small risks of pelvic infection (<1%), mild uterine cramping, localized spotting, or extremely rare uterine perforation (<0.1%). Pharmacotherapy risks vary by prescribed agent, such as minor bleeding risks associated with low-dose aspirin or low-molecular-weight heparin.

Clinical Care Trajectory

The patient journey at a recurrent pregnancy loss clinic spans four primary phases:

• Initial Consultation and Pre-Test Workup: Detailed history taking, review of prior pregnancy losses, genetic counseling, and baseline blood sampling.
• Diagnostic Testing: Comprehensive evaluation including uterine cavity imaging (such as 3D transvaginal ultrasonography or hysteroscopy), parental karyotyping, thrombophilia testing, and endocrine panels.
• Targeted Treatment Implementation: Medical or surgical intervention tailored to diagnosed abnormalities, such as hormonal rebalancing, surgical correction of uterine septa, or anticoagulation therapy.
• Early Obstetric Surveillance: Intensive serial monitoring during early gestation, including serial quantitative human chorionic gonadotropin (hCG) tracking and early serial pelvic ultrasounds.